Signal/NN
transduction/NN
abnormalities/NNS
in/IN
T/NN
lymphocytes/NNS
from/IN
patients/NNS
with/IN
advanced/JJ
renal/JJ
carcinoma/NN
:/:
clinical/JJ
relevance/NN
and/CC
effects/NNS
of/IN
cytokine/NN
therapy/NN
./.

Studies/NNS
have/VBP
demonstrated/VBN
abnormalities/NNS
of/IN
the/DT
CD3/T-cell/NN
antigen/NN
receptor/NN
(/(
TCR/NN
)/)
and/CC
pathways/NNS
of/IN
signal/NN
transduction/NN
in/IN
T/NN
lymphocytes/NNS
from/IN
animals/NNS
and/CC
patients/NNS
with/IN
advanced/JJ
malignancy/NN
./.
=====
Diminished/VBN
expression/NN
of/IN
TCRzeta/NN
and/CC
p56(lck)/NN
that/WDT
are/VBP
associated/VBN
with/IN
the/DT
TCR/NN
and/CC
reduced/VBN
nuclear/JJ
localization/NN
of/IN
RelA/NN
containing/VBG
nuclear/JJ
factor/NN
kappaB/NN
(/(
NFkappaB/NN
)/)
complexes/NNS
have/VBP
been/VBN
noted/VBN
./.
=====
These/DT
defects/NNS
have/VBP
been/VBN
described/VBN
in/IN
T/NN
cells/NNS
from/IN
patients/NNS
with/IN
malignant/JJ
melanoma/NN
,/,
renal/JJ
cell/NN
carcinoma/NN
(/(
RCC/NN
)/)
,/,
ovarian/JJ
cancer/NN
,/,
and/CC
colorectal/JJ
cancer/NN
./.
=====
Preliminary/JJ
observations/NNS
also/RB
indicate/VBP
possible/JJ
correlation/NN
with/IN
clinical/JJ
variables/NNS
such/JJ
as/IN
stage/NN
in/IN
selected/VBN
instances/NNS
./.
=====
To/TO
further/RB
characterize/VB
altered/JJ
expression/NN
of/IN
TCRzeta/NN
,/,
p56(lck)/NN
,/,
and/CC
impaired/JJ
activation/NN
of/IN
NFkappaB/NN
,/,
T/NN
lymphocytes/NNS
were/VBD
obtained/VBN
from/IN
65/CD
patients/NNS
with/IN
RCC/NN
,/,
the/DT
majority/NN
of/IN
whom/WP
were/VBD
receiving/VBG
combination/NN
cytokine/NN
therapy/NN
[/(
interleukin/NN
(/(
IL/NN
)/)
-2/CD
,/,
IFN/NN
alpha-containing/JJ
regimens/NNS
]/)
and/CC
37/CD
control/JJ
individuals/NNS
./.
=====
In/IN
29/CD
of/IN
these/DT
patients/NNS
,/,
levels/NNS
of/IN
TCRzeta/NN
and/CC
p56(lck)/NN
were/VBD
determined/VBN
by/IN
Western/NN
blots/NNS
of/IN
T-cell/NN
lysates/NNS
and/CC
semiquantitated/VBN
using/VBG
densitometry/NN
./.
=====
Relative/JJ
levels/NNS
were/VBD
then/RB
correlated/VBN
with/IN
a/DT
series/NN
of/IN
clinical/JJ
variables/NNS
including/VBG
response/NN
to/TO
therapy/NN
,/,
performance/NN
status/NN
,/,
survival/NN
,/,
disease/NN
sites/NNS
,/,
age/NN
,/,
and/CC
others/NNS
./.
=====
In/IN
another/DT
group/NN
of/IN
28/CD
patients/NNS
(/(
three/CD
individuals/NNS
from/IN
the/DT
first/JJ
group/NN
)/)
,/,
the/DT
frequency/NN
of/IN
abnormal/JJ
NFkappaB/NN
activation/NN
was/VBD
studied/VBN
using/VBG
electrophoretic/JJ
mobility/NN
shift/NN
assays/NNS
after/IN
activation/NN
of/IN
T/NN
cells/NNS
with/IN
phorbol/NN
myristate/NN
acetate/ionomycin/NN
or/CC
anti-CD3/JJ
monoclonal/JJ
antibody/NN
./.
=====
Changes/NNS
in/IN
these/DT
signaling/VBG
molecules/NNS
during/IN
cytokine/NN
treatment/NN
were/VBD
also/RB
investigated/VBN
./.
=====
TCRzeta/NN
and/CC
p56(lck)/NN
were/VBD
detected/VBN
in/IN
the/DT
peripheral/JJ
blood/NN
T/NN
cells/NNS
in/IN
27/CD
of/IN
29/CD
patients/NNS
,/,
and/CC
overall/RB
,/,
reduced/VBN
levels/NNS
were/VBD
noted/VBN
visually/RB
in/IN
12/CD
of/IN
29/CD
(/(
41/CD
%/NN
)/)
and/CC
13/CD
of/IN
29/CD
(/(
45/CD
%/NN
)/)
individuals/NNS
,/,
respectively/RB
./.
=====
When/WRB
levels/NNS
were/VBD
semiquantitated/VBN
using/VBG
densitometry/NN
,/,
significant/JJ
decreases/NNS
of/IN
TCRzeta/NN
(/(
P/NN
=/JJ
0.029/CD
)/)
and/CC
p56(lck)/NN
(/(
P/NN
=/JJ
0.029/CD
)/)
but/CC
not/RB
CD3epsilon/NN
(/(
P/NN
=/JJ
0.131/CD
)/)
,/,
compared/VBN
with/IN
control/NN
levels/NNS
,/,
were/VBD
found/VBN
./.
=====
In/IN
patients/NNS
treated/VBN
with/IN
IL-2/IFN/NN
alpha-based/JJ
therapy/NN
,/,
relative/JJ
levels/NNS
of/IN
TCRzeta/NN
increased/VBD
significantly/RB
(/(
P/NN
=/JJ
0.002/CD
)/)
on/IN
day/NN
15/CD
of/IN
cycle/NN
one/CD
compared/VBN
with/IN
the/DT
baseline/NN
./.
=====
Correlations/NNS
of/IN
TCRzeta/NN
or/CC
p56(lck)/NN
levels/NNS
with/IN
response/NN
or/CC
disease/NN
variables/NNS
,/,
except/IN
for/IN
lower/JJR
TCRzeta/NN
levels/NNS
(/(
P/NN
</JJR
0.001/CD
)/)
in/IN
the/DT
presence/NN
of/IN
bone/NN
metastases/NNS
,/,
were/VBD
not/RB
found/VBN
./.
=====
Abnormal/JJ
NFkappaB/NN
activation/NN
after/IN
stimulation/NN
with/IN
phorbol/NN
myristate/NN
acetate/ionomycin/NN
and/or/CC
anti-CD3/JJ
monoclonal/JJ
antibody/NN
was/VBD
found/VBN
in/IN
59/CD
%/NN
of/IN
patients/NNS
(/(
17/CD
of/IN
28/CD
)/)
and/CC
was/VBD
not/RB
accounted/VBN
for/IN
by/IN
the/DT
advanced/JJ
age/NN
of/IN
the/DT
study/NN
cohort/NN
./.
=====
Activation/NN
of/IN
NFkappaB/NN
in/IN
peripheral/JJ
blood/NN
T/NN
cells/NNS
was/VBD
inducible/JJ
during/IN
cytokine/NN
therapy/NN
in/IN
four/CD
of/IN
six/CD
individuals/NNS
who/WP
displayed/VBD
impaired/JJ
NFkappaB/NN
activity/NN
prior/RB
to/TO
therapy/NN
./.
=====
Moreover/RB
,/,
impaired/JJ
activation/NN
of/IN
NFkappaB/NN
does/VBZ
not/RB
appear/VB
linked/VBN
to/TO
a/DT
reduction/NN
of/IN
TCRzeta/NN
expression/NN
,/,
because/IN
in/IN
five/CD
patients/NNS
,/,
normal/JJ
TCRzeta/NN
levels/NNS
were/VBD
present/JJ
although/IN
kappaB/NN
binding/NN
was/VBD
not/RB
inducible/JJ
./.
=====
In/IN
the/DT
majority/NN
of/IN
patients/NNS
with/IN
advanced/JJ
RCC/NN
,/,
peripheral/JJ
blood/NN
T/NN
cells/NNS
express/VBP
TCRzeta/NN
and/CC
p56(lck)/NN
,/,
and/CC
in/IN
a/DT
subset/NN
,/,
reduced/VBN
levels/NNS
of/IN
these/DT
TCRzeta/NN
associated/JJ
molecules/NNS
are/VBP
seen/VBN
that/WDT
may/MD
increase/VB
during/IN
cytokine-based/JJ
therapy/NN
./.
=====
Abnormal/JJ
activation/NN
of/IN
NFkappaB/NN
is/VBZ
also/RB
present/JJ
in/IN
>/JJR
50/CD
%/NN
of/IN
patients/NNS
and/CC
may/MD
also/RB
revert/VB
to/TO
normal/JJ
during/IN
IL-2/IFN/NN
alpha-based/JJ
treatment/NN
./.
=====
This/DT
alteration/NN
in/IN
NFkappaB/NN
activation/NN
occurred/VBD
in/IN
the/DT
presence/NN
of/IN
normal/JJ
expression/NN
of/IN
TCRzeta-associated/JJ
signaling/NN
elements/NNS
./.
=====
The/DT
clinical/JJ
significance/NN
of/IN
these/DT
findings/NNS
remains/VBZ
unclear/JJ
./.